Ibrutinib Plus Rituximab Superior To Standard Treatment For Patients With Chronic Leukemia | Latest News RSS feed

Ibrutinib Plus Rituximab Superior To Standard Treatment For Patients With Chronic Leukemia - Latest News


Imbruvica May Be Superior to Standard of Care in Elderly Patients with CLL

Imbruvica (ibrutinib) may be superior to standard of care in elderly patients with untreated chronic lymphocytic leukemia (CLL), according to ... a type of chemotherapy, and Rituxan (rituximab), an im... read more

Phase 3 trial finds ibrutinib in combo with rituximab superior to standard treatment for some patients with CLL

An interim analysis of a large phase 3 clinical trial found that the combination of ibrutinib plus rituximab was superior to standard treatment for patients age 70 and younger with previously untreate... read more

Ibrutinib outperforms chemoimmunotherapy in older patients with chronic lymphocytic leukemia

Results from an multi-institutional, phase 3 clinical trial show that older patients with chronic lymphocytic leukemia ... ibrutinib to bendamustine plus rituximab, a more effective regimen. "Our resu... read more

Looking for another news?


Updates in Chronic Lymphocytic Leukemia: 60th ASH Annual Meeting

Presentations at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition were dominated by advancements in the treatment of chronic lymphocytic leukemia ... this patient population. ... read more


Ibrutinib/R-CHOP Fails to Meet Primary Endpoint in Phase III DLBCL Trial

In the DBL3001 trial, the combination of ibrutinib and R-CHOP was not superior to treatment ... therapy in some patients.” Ibrutinib is currently approved by the US Food and Drug Administration for pa... read more

Late-Breaking Clinical Trials Advance Targeted Therapies for Patients with CLL and Multiple Myeloma

Ibrutinib-Based Therapy More Effective, Safer in Younger Patients with Previously Untreated CLL Compared with Current Standard ... plus rituximab (FCR) has historically been the most effective treatme... read more

USFDA approved leukemia drug more effective than standard treatment

The drug, ibrutinib ... ibrutinib plus rituximab. About 17 per cent of patients who received ibrutinib alone experienced an irregular heartbeat called atrial fibrillation. But overall, the drug caused ... read more

Major Trials Show Benefits of New Therapy Regimens for Cancer and Blood Disorders

"They address important questions relevant to improving treatment ... Older Patients with Chronic Lymphocytic Leukemia Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Fr... read more

Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options

IS THERE STILL A ROLE FOR CHEMOIMMUNOTHERAPY IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA? Patients with del(17p) are resistant to CIT. Results with targeted therapies, such as ibrutinib and venet... read more

COUNTERPOINT: Does Chemoimmunotherapy Still Have a Role in CLL?

For the older patient population, while bendamustine plus rituximab and chlorambucil plus obinutuzumab are effective, ibrutinib appears to have superior ... ibrutinib in treatment-naïve and relapsed/r... read more

New leukemia drug is more effective and easier to use

A landmark study co-authored by a Loyola Medicine oncologist has found that a newer targeted drug is significantly more effective than standard therapy for treating elderly patients with chronic ... t... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us